Results from two international clinical trials yield promising results for halting the mestatise of melanoma, yield novel treatment options for melanoma and may help stop this form of cancer metastizing.
Novel research has indicated a distinct group of circulating tumor cells that are associated with breast cancer brain metastases, the findings may help detect the tumors while they are still treatable.
This review outlines the strengths and limitations of each of the different imaging modalities for prostate cancer as well as individual tracers used, including preclinical and clinical agents.
Researchers have discovered a potential new method of stopping metastasis by simultaneously inhibiting IL-6 and IL-8 paracrine signalling pathways.
Researchers have demonstrated that pre-invasive breast cancer cells undergo a stiffening state, through actin-stress fiber organization, prior to becoming malignant.
Does Graded Prognostic Assessment outperform Recursive Partitioning Analysis in patients with moderate prognosis brain metastases?
Primary research to evaluate whether Recursive Partitioning Analysis or Graded Prognostic Assessment is more useful to clinicians.
The largest-known study in thyroid cancer patients highlights that skeletal complications in high-risk follicular and medullary thyroid cancer patients are an indicator of poor prognosis.
Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors
Discover more about the molecular profiles of brain metastases from colorectal cancer and corresponding primary tumors with a focus on KRAS, NRAS, BRAF and PIK3CA in this research article from Future Oncology.
The US FDA has granted accelerated approval to the immune checkpoint inhibitor avelumab for treating metastatic merkel cell carcinoma patients, the first FDA approved drug for the cancer.
Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature
In this case report the authors present systematic therapy as a multimodality tool in the management of patients with oligometastatic disease.